This site is intended for U.S. health care professionals only.

Billing and coding information

Permanent Product-Specific J Code Supports Billing and Coding

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent product-specific J-code (J2407) for ORBACTIV Injection. The unique J-code recognizes the distinct value of ORBACTIV simplifies billing and coding, and enables reimbursement of ORBACTIV in all outpatient treatment settings.*

*5 Fed. Reg. 85866,85869 (Dec. 29, 2020)

 

Healthcare Common Procedure Coding System (HCPCS) Codes

 
The following are the drug codes for appropriate billing. Medicare, private payers, and state Medicaid programs require UB-04 (CMS-1450) claim forms (for Hospital Outpatient setting) or CMS-1500 (for Freestanding Infusion Center setting) to report the following codes and amount of product used to facilitate appropriate reimbursement1 .

 

Settings

HCPCS

Billing Description

Billing Unit

Hospital Outpatient § J2407 Injection, oritavancin, 10mg 120 units
(1200 mg = 120 billing units)
Freestanding Infusion Centers and Physician Offices § J2407 Injection, oritavancin, 10mg 120 units
(1200 mg = 120 billing units)
§ Please note: Other payors may require different billing units. Please follow payor guidance.

Accurate reporting of the ORBACTIV® HCPCS code, as well as the quantity administered to each patient, is required for appropriate reimbursement. When completing a UB-04/ CMS 1450 or CMS 1500 form for ORBACTIV®, payers may also require the following information:

Drug Name ORBACTIV ® (oritavancin) for injection
Route of Administration By intravenous infusion over 3 hours
Quantity Administered 1200 mg
Dose of Product 1200 mg
NDC 70842-140-01 ORBACTIV. Single 400 mg vial
70842-140-03 ORBACTIV. Carton containing three 400 mg vials One vial is packaged in a carton to supply a single 1200 mg dose treatment.
Packaging (e.g., single dose vial) 3 vials packaged in a carton to supply a single 1200 mg dose treatment


Some payers may also require prescribing information, FDA-approval letter, support of medical necessity and a drug purchase invoice.

For additional information regarding Billing and Coding, please:
Refer to the ORBACTIV Reimbursement Guide

Contact the ORBACTIV Support Program
1-844-ORBACTIV (1-844-672-2284)
Email: OrbactivSupport@Asembia.com
Monday-Friday 8:00 AM to 8:00 PM, ET

1. Centers for Medicare & Medicaid Services. CMS website. MLN Matters MM11814 Revised July 2020. Update of the Hospital Outpatient Prospective Payment System (OPPS). https://www.cms.gov/files/document/mm11814.pdf. Accessed August 19, 2021; Centers for Medicare & Medicaid Services. CMS website. MLN Matters MM11842 Revised July 2020. Update of the Ambulatory Surgical Center Prospective Payment System (ASC). https://www.cms.gov/files/document/mm11842.pdf. Accessed August 19, 2021.

DISCLAIMER

Content provided for informational purposes only. This information does not guarantee coverage or payment. Codes, coverage, and payment may vary from setting to setting, and from insurer to insurer. The provider submitting a claim is solely responsible for the accuracy of the codes submitted and for compliance with all coverage and reimbursement policies.

Decisions to prescribe ORBACTIV® are by providers working with their patients. The ORBACTIV® Support Program provides information about ORBACTIV® and about assistance that may be available to patients who meet certain criteria, including that they are not insured by a federal health care program. More information is available through the ORBACTIV® Support Program.

Melinta Therapeutics, LLC, does not guarantee, and assumes no responsibility for the quality, availability, or scope of the ORBACTIV® Support Program services. Melinta Therapeutics, LLC, reserves the right to rescind, revoke, or amend this offer at any time without notice. Void where prohibited by law.

INDICATION AND USAGE

ORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV® and other antibacterial drugs, ORBACTIV® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Important Safety Information

Contraindications

Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after ORBACTIV® administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for approximately 120 hours (5 days) after ORBACTIV® administration.

ORBACTIV® is contraindicated in patients with known hypersensitivity to oritavancin products.

Warnings and Precautions

Coagulation test interference: Oritavancin has been shown to artificially prolong aPTT for up to 120 hours and may prolong PT and INR for up to 12 hours, and ACT for up to 24 hours. Oritavancin has also been shown to elevate D-dimer concentrations up to 72 hours. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products, including ORBACTIV®. Discontinue infusion if signs of acute hypersensitivity occur. Closely monitor patients with known hypersensitivity to glycopeptides.

Infusion Related Reactions: Administer ORBACTIV® over 3 hours to minimize infusion-related reactions. Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products (e.g. ORBACTIV®), including after the administration of more than one dose of oritavancin during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.

Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving ORBACTIV® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing ORBACTIV® in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥3%) in patients treated with ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.

Please see Full Prescribing Information for ORBACTIV®.

INDICATION AND USAGE

ORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV® and other antibacterial drugs, ORBACTIV® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.